Merck & Co. Statistics
Total Valuation
Merck & Co. has a market cap or net worth of $278.87 billion. The enterprise value is $314.13 billion.
| Market Cap | 278.87B |
| Enterprise Value | 314.13B |
Important Dates
The next confirmed earnings date is Thursday, April 30, 2026, before market open.
| Earnings Date | Apr 30, 2026 |
| Ex-Dividend Date | Mar 16, 2026 |
Share Statistics
Merck & Co. has 2.47 billion shares outstanding. The number of shares has decreased by -1.34% in one year.
| Current Share Class | 2.47B |
| Shares Outstanding | 2.47B |
| Shares Change (YoY) | -1.34% |
| Shares Change (QoQ) | -0.40% |
| Owned by Insiders (%) | 0.05% |
| Owned by Institutions (%) | 80.16% |
| Float | 2.47B |
Valuation Ratios
The trailing PE ratio is 15.46 and the forward PE ratio is 22.03. Merck & Co.'s PEG ratio is 2.68.
| PE Ratio | 15.46 |
| Forward PE | 22.03 |
| PS Ratio | 4.28 |
| Forward PS | 4.13 |
| PB Ratio | 5.29 |
| P/TBV Ratio | 64.00 |
| P/FCF Ratio | 22.50 |
| P/OCF Ratio | 16.89 |
| PEG Ratio | 2.68 |
Enterprise Valuation
The stock's EV/EBITDA ratio is 10.79, with an EV/FCF ratio of 25.41.
| EV / Earnings | 17.21 |
| EV / Sales | 4.83 |
| EV / EBITDA | 10.79 |
| EV / EBIT | 12.84 |
| EV / FCF | 25.41 |
Financial Position
The company has a current ratio of 1.54, with a Debt / Equity ratio of 0.96.
| Current Ratio | 1.54 |
| Quick Ratio | 0.96 |
| Debt / Equity | 0.96 |
| Debt / EBITDA | 1.71 |
| Debt / FCF | 4.09 |
| Interest Coverage | 18.03 |
Financial Efficiency
Return on equity (ROE) is 36.88% and return on invested capital (ROIC) is 25.91%.
| Return on Equity (ROE) | 36.88% |
| Return on Assets (ROA) | 12.04% |
| Return on Invested Capital (ROIC) | 25.91% |
| Return on Capital Employed (ROCE) | 22.54% |
| Weighted Average Cost of Capital (WACC) | 5.24% |
| Revenue Per Employee | $866,813 |
| Profits Per Employee | $243,387 |
| Employee Count | 75,000 |
| Asset Turnover | 0.51 |
| Inventory Turnover | 2.32 |
Taxes
In the past 12 months, Merck & Co. has paid $2.80 billion in taxes.
| Income Tax | 2.80B |
| Effective Tax Rate | 13.31% |
Stock Price Statistics
The stock price has increased by +45.05% in the last 52 weeks. The beta is 0.28, so Merck & Co.'s price volatility has been lower than the market average.
| Beta (5Y) | 0.28 |
| 52-Week Price Change | +45.05% |
| 50-Day Moving Average | 118.80 |
| 200-Day Moving Average | 98.90 |
| Relative Strength Index (RSI) | 38.17 |
| Average Volume (20 Days) | 8,981,048 |
Short Selling Information
The latest short interest is 27.72 million, so 1.12% of the outstanding shares have been sold short.
| Short Interest | 27.72M |
| Short Previous Month | 31.12M |
| Short % of Shares Out | 1.12% |
| Short % of Float | 1.12% |
| Short Ratio (days to cover) | 2.69 |
Income Statement
In the last 12 months, Merck & Co. had revenue of $65.01 billion and earned $18.25 billion in profits. Earnings per share was $7.28.
| Revenue | 65.01B |
| Gross Profit | 50.20B |
| Operating Income | 24.47B |
| Pretax Income | 21.07B |
| Net Income | 18.25B |
| EBITDA | 29.11B |
| EBIT | 24.47B |
| Earnings Per Share (EPS) | $7.28 |
Balance Sheet
The company has $14.57 billion in cash and $50.53 billion in debt, with a net cash position of -$35.97 billion or -$14.56 per share.
| Cash & Cash Equivalents | 14.57B |
| Total Debt | 50.53B |
| Net Cash | -35.97B |
| Net Cash Per Share | -$14.56 |
| Equity (Book Value) | 52.66B |
| Book Value Per Share | 21.26 |
| Working Capital | 15.19B |
Cash Flow
In the last 12 months, operating cash flow was $16.47 billion and capital expenditures -$4.11 billion, giving a free cash flow of $12.36 billion.
| Operating Cash Flow | 16.47B |
| Capital Expenditures | -4.11B |
| Depreciation & Amortization | 4.64B |
| Net Borrowing | 11.38B |
| Free Cash Flow | 12.36B |
| FCF Per Share | $5.00 |
Margins
Gross margin is 77.21%, with operating and profit margins of 37.64% and 28.08%.
| Gross Margin | 77.21% |
| Operating Margin | 37.64% |
| Pretax Margin | 32.41% |
| Profit Margin | 28.08% |
| EBITDA Margin | 44.77% |
| EBIT Margin | 37.64% |
| FCF Margin | 19.01% |
Dividends & Yields
This stock pays an annual dividend of $3.40, which amounts to a dividend yield of 3.01%.
| Dividend Per Share | $3.40 |
| Dividend Yield | 3.01% |
| Dividend Growth (YoY) | 5.06% |
| Years of Dividend Growth | 15 |
| Payout Ratio | 45.60% |
| Buyback Yield | 1.34% |
| Shareholder Yield | 4.35% |
| Earnings Yield | 6.56% |
| FCF Yield | 4.44% |
Analyst Forecast
The average price target for Merck & Co. is $125.59, which is 11.23% higher than the current price. The consensus rating is "Buy".
| Price Target | $125.59 |
| Price Target Difference | 11.23% |
| Analyst Consensus | Buy |
| Analyst Count | 17 |
| Revenue Growth Forecast (5Y) | 1.58% |
| EPS Growth Forecast (5Y) | 4.34% |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | |
| Lynch Upside | |
| Graham Number | |
| Graham Upside |
Stock Splits
The last stock split was on February 17, 1999. It was a forward split with a ratio of 2:1.
| Last Split Date | Feb 17, 1999 |
| Split Type | Forward |
| Split Ratio | 2:1 |
Scores
Merck & Co. has an Altman Z-Score of 3.5 and a Piotroski F-Score of 5.
| Altman Z-Score | 3.5 |
| Piotroski F-Score | 5 |